SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Combined antithrombotic therapy vs. oral anticoagulation alone for ischemic stroke with concomitant atrial fibrillation and large artery atherosclerosis: a systematic review and meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreating ischemic stroke patients who have both nonvalvular atrial fibrillation (NVAF) and large artery atherosclerosis (LAA) presents a clinical challenge. It remains unclear whether adding antiplatelet therapy (APT) to oral anticoagulation (OAC) reduces stroke risk or only increases the danger of hemorrhage.
methodsWe conducted a systematic review and meta-analysis of randomized and observational studies to compare OAC monotherapy against combined therapy (OAC + APT) in patients with recent ischemic stroke, NVAF, and LAA. PubMed, Embase, Scopus, Cochrane Library, and Web of Science were searched from inception to December 2025. We applied random-effects models to estimate Risk Ratios (RR).
resultsSeven studies comprising 14,884 patients were included. Combined therapy was not associated with a significant reduction in recurrent ischemic stroke (RR 0.98; 95% CI: 0.92-1.04; p = 0.55) or all-cause mortality (RR 1.11; 95% CI: 0.98-1.26; p = 0.09) compared to OAC monotherapy. Conversely, the combined strategy was associated with a statistically significant increase in the risk of major bleeding (RR 1.49; 95% CI: 1.04-2.15; p = 0.03).
conclusionOur findings indicate that adding antiplatelets to anticoagulation in patients with stroke, AF, and LAA confers no real clinical benefit but significantly exacerbates hemorrhagic morbidity. Consequently, OAC monotherapy should remain the standard of care, while combined therapy should be avoided in routine practice.
Indexed as
Identifiers
42640340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.